Search clinical trials for: Aromatase inhibitor

Total 64709 results

Massachusetts General Hospital
National Institutes of Health (NIH); American Diabetes Association

Terminated

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

Metabolic Syndrome

United States
Ain Shams University

Completed

Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion

Miscarriage

Egypt
Hoffmann-La Roche
Genentech, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

Breast Cancer

Italy, Spain, Sweden, China, Hong Kong, Canada, South Africa, Ukraine, United States, United Kingdom, Russian Federation, Taiwan, Australia, Mexico, Turkey, Israel, Poland, Bulgaria, Germany, France, Netherlands, Norway, India, Hungary, Brazi... and more
Zagazig University

Completed

Study to Compare Between Combimed Metformin-letrozole and Ovarian Drilling in Pcos With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome

Focus of Study

Egypt
AstraZeneca
German Adjuvant Breast Cancer Group

Completed

Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women. (ARNO-95)

Breast Cancer

Germany
Avenzo Therapeutics, Inc.

Recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Washington University School of Medicine
Pfizer

Active, not recruiting

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Breast Neoplasms

United States
Sanofi

Terminated

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (AMEERA-5)

Breast Cancer

United States, Russian Federation, Italy, Australia, Belgium, France, Japan, Ukraine, Netherlands, Argentina, Canada, Portugal, Spain, Austria, Brazil, Bulgaria, Chile, China, Czechia, Finland, Georgia, Germany, Hungary, Korea, Republic... and more
Palleos Healthcare GmbH
Pfizer; Cankado GmbH; WSG WOMEN´S HEALTHCARE STUDY GROUP; AGO-TraFo; AGO-B; Deutsche...

Terminated

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (PRECYCLE)

Breast Neoplasm

Germany
MedSIR
Pfizer

Completed

Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 - (DxCARTES)

Breast Cancer

Spain, Portugal
Merck Sharp & Dohme LLC

Not yet recruiting

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Metastatic Breast Cancer
AstraZeneca

Not yet recruiting

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01)

Advanced Breast Cancer

Canada
Pfizer

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Korea, Republic of, Japan
Spanish Breast Cancer Research Group
Pfizer; AstraZeneca

Completed

Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors (PEARL)

Metastatic Breast Cancer

Spain, Israel, Hungary, Austria
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Ductal Carcinoma in Situ

United States
Gruppo Italiano Mammella (GIM)

Unknown

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Breast Cancer

Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer

Breast Cancer

United States
Ruth O'Regan
University of Rochester; Puma Biotechnology, Inc.

Recruiting

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Breast Cancer | HER2-positive Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer

United States
ARCAGY/ GINECO GROUP

Terminated

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

First Line Metastatic Breast Cancer

France
Jules Bordet Institute
Novartis

Completed

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women (PEARL)

Breast Cancer

Belgium
Bayer

Completed

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Breast Neoplasms

Belgium, Spain, Hong Kong, Taiwan, Japan, United States, Austria, Singapore, Israel, United Kingdom, Italy, Korea, Republic of, France, Poland, Switzerland, Germany, Norway
University of Alabama at Birmingham
Genentech, Inc.

Completed

Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

Breast Cancer

United States
Atossa Therapeutics, Inc.
InClin

Recruiting

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE)

Breast Neoplasms | Invasive Breast Cancer | HER2-negative Breast Cancer | Estrogen-receptor-positive Breast Cancer

United States
M.D. Anderson Cancer Center
Zymeworks BC Inc.

Active, not recruiting

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Breast Cancer | HER2-positive

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Musculoskeletal Complications

United States
Ahon Pharmaceutical Co., Ltd.
Zhejiang Cancer Hospital; Fudan University; Sir Run Run Shaw Hospital

Unknown

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Breast Neoplasms

China
NYU Langone Health

Completed

Exemestane and Cyclophosphamide for Metastatic Breast Cancer

Metastatic Beast Cancer

United States
Ain Shams University

Unknown

Laparoscopic Ovarian Drilling Versus Letrozole In Clomiphene Citrate Resistant Polycystic Ovary

Induction of Ovulation

Egypt
Ottawa Hospital Research Institute

Unknown

The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers (OTT 17-01)

Breast Cancer
Novartis Pharmaceuticals
University of Sheffield; Danish Breast Cancer Cooperative Group

Completed

A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer

Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women

Denmark, United Kingdom
Buddhist Tzu Chi General Hospital
China Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical... and other collaborators

Unknown

A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix (TGOG1005)

Uterine Cervical Neoplasms

Taiwan
AstraZeneca

Completed

ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.

Breast Cancer

Austria
AstraZeneca

Completed

ATAC - Pharmacokinetics (PK) Sub-Protocol

Breast Cancer
AstraZeneca
Institute of Cancer Research, United Kingdom

Completed

ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years

Breast Cancer

Italy
Escola Bahiana de Medicina e Saude Publica

Completed

Photodynamic Therapy Associated With Full-mouth Ultrasonic Debridement in the Treatment of Severe Chronic Periodontitis

Chronic Periodontitis
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Breast Cancer

China
Novartis Pharmaceuticals

Suspended

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (Adjuvant WIDER)

Early Breast Cancer

Australia
Zagazig University

Active, not recruiting

Letrozole as a Prophylaxis From GTN for Complete Mole Patients

Gestational Trophoblastic Disease

Egypt
Actavis Inc.

Withdrawn

Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects

Healthy

South Africa
Mayo Clinic

Completed

Impact of Estradiol Addback

Normal Healthy Volunteers

United States
Navy General Hospital, Beijing

Unknown

Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer

Female Infertility Due to Nonimplantation of Ovum

China
Benha University

Completed

Dual FSH/HCG Trigger in Letrozole Stimulated Intrauterine Insemination Cycles in Women With Unexplained Infertility

Unexplained Infertility
Kristina Gemzell Danielsson
Karolinska Institutet; The University of Hong Kong

Terminated

Randomized Study of Letrozole and Trilostane for Medical Abortion

Medical Abortion, Complete or Unspecified, Without Complication

Sweden
AstraZeneca

Completed

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Progression-free Survival

Korea, Republic of
Mansoura University

Completed

Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis

the Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine Adenomyosis

Egypt
AstraZeneca

Completed

ATAC - Quality of Life Sub-Protocol

Quality of Life
AstraZeneca

Completed

ATAC - Bone Density Sub-Protocol

Bone Density
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Memorial Sloan Kettering Cancer Center
Context Therapeutics Inc.

Active, not recruiting

A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

Granulosa Cell Ovarian Cancer | Low Grade Serous Ovarian/ Primary Peritoneal Cancer | Endometrioid Endometrial Cancer

United States

Search clinical trials for: Aromatase inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations